Osteopore Ltd
Osteopore Limited is a regenerative medicine company engaged in three-dimensional (3D)-printed biomimetic and bioresorbable implants.
The business
Osteopore Limited is a regenerative medicine company engaged in three-dimensional (3D)-printed biomimetic and bioresorbable implants. The Company’s commercialized products are designed to enable natural bone healing across multiple therapeutic areas. The Company’s patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. Through its proprietary manufacturing process, which uses a naturally dissolving polymer, its patented scaffolds enable bone tissue growth, significantly reducing the post-surgery complications commonly associated with permanent bone implants. The Company’s surgical specialty includes craniotomy, orbital floor reconstruction, socket preservation, cranioplasty patient-specific implants (PSI), craniosynostosis, guided bone regeneration, endoscopic transsphenoidal skull base surgery, burr hole restoration with the shunt drainage system, mandible PSI, and immediate implant loading, among others.
Small Caps Research
No research on Osteopore Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise OSX based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Osteopore Expands Orthopaedic Business into Hong Kong with MontsMed Distribution Agreement
Osteopore (ASX: OSX) is set to expand its orthopaedic business into Hong Kong after signing a new distribution agreement with local company MontsMed, marking the next step in the company’s planned commercial expansion across the Asia Pacific region.
Osteopore Granted Swiss Market Approval for Custom Bioresorbable Implants
Regenerative medicine company Osteopore (ASX: OSX) has secured market approval in Switzerland for its off-the-shelf and custom-made biomimetic and bioresorbable implants. Approval came under the European Union’s medical device regulations (MDR) and follows the company’s partnership with US orthopaedic solutions company Zimmer Biomet to distribute its craniofacial products in Europe, the Middle East and Africa, the […]
Osteopore granted European market approval for custom orthopaedic and cranial implants
Regenerative medicine company Osteopore (ASX: OSX) has secured European Union medical device regulation approval for its custom orthopaedic and cranial implants. The approval unlocks opportunities for the company to offer high-value custom implants to the European market to complement its range of off-the-shelf neurosurgical and craniofacial implants. Osteopore will distribute the products via an exclusive […]
Osteopore granted regulatory approval for innovative bone reconstruction procedures in Singapore and Vietnam
Regenerative medicine specialist Osteopore (ASX: OSX) is set to help relieve the knee pain of thousands of sufferers with the company now able to use several of its procedures in Singapore and Vietnam. In a milestone for Osteopore’s growth strategy, the company’s aXOpore technology has been granted regulatory clearance by Singapore’s Health Sciences Authority and […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.